Cardinal Health, Inc. (CAH) - Q2 Fiscal 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2024 (Q2 Fiscal 2025). Cardinal Health operates as a global healthcare services and products company with two primary reportable segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD). The company reported under a new organizational structure effective January 1, 2024, which recast prior period results. The fiscal year ends on June 30.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $55.3 billion | $57.4 billion | $107.5 billion | $112.1 billion |
| GAAP Operating Earnings | $549 million | $505 million | $1.1 billion | $473 million |
| Non-GAAP Operating Earnings | $635 million | $585 million | $1.3 billion | $1.1 billion |
| GAAP Diluted EPS | $1.65 | $1.50 | $3.35 | $1.43 |
| Non-GAAP Diluted EPS | $1.93 | $1.89 | $3.81 | $3.60 |
| Gross Margin | $1.9 billion (3.51%) | $1.9 billion (3.49%) | $3.8 billion (3.57%) | $3.6 billion (3.21%) |
| Cash and Equivalents | $3.8 billion (as of Dec 31, 2024) | |||
| Total Long-Term Debt | $7.6 billion (as of Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenue decreased 4% year-over-year for both the quarter and six-month periods. This was primarily driven by the expiration of pharmaceutical distribution contracts with OptumRx in June 2024, which accounted for 17% of fiscal 2024 revenue. This decline was partially offset by growth in branded and specialty pharmaceutical sales.
- Profitability Improvement: GAAP operating earnings increased 9% for the quarter and significantly for the six-month period (driven by a $585 million goodwill impairment charge in the prior year's GMPD segment). Non-GAAP operating earnings grew 9% and 10% for the quarter and six months, respectively, due to cost savings and growth in BioPharma Solutions.
- Cash Flow: Net cash used in operating activities was $2.0 billion for the six months ended December 31, 2024. This usage was primarily due to the unwinding of negative net working capital associated with the OptumRx contracts, normal vendor payment timing, and $692 million in opioid litigation payments.
- Debt Issuance: The company issued $2.9 billion in new long-term debt in November 2024 to fund acquisitions and general purposes, increasing total long-term obligations from $5.1 billion to $7.6 billion.
Guidance, Outlook, and Risks
- Acquisitions:
- Completed: Acquired Integrated Oncology Network (ION) for $1.1 billion (Dec 2024) and a 73% stake in GI Alliance (GIA) for $2.8 billion (Jan 2025).
- Pending: Agreed to acquire Advanced Diabetes Supply Group (ADSG) for $1.1 billion, subject to regulatory approval.
- Outlook: Management expects the expiration of OptumRx contracts to continue to have adverse impacts on results throughout the remainder of fiscal 2025, though they anticipate offsetting this through new customer onboarding and cost savings. The new acquisitions are expected to positively impact segment revenue and profit but will increase amortization costs.
- Risks and Contingencies:
- Opioid Litigation: $4.9 billion is accrued for opioid-related settlements. Payments are expected to continue through 2038.
- Goodwill Impairment: The at-Home Solutions reporting unit's fair value exceeded its carrying amount by less than 1% in the last annual test, indicating sensitivity to future cash flow changes.
- Regulatory/Trade: Risks include changes in U.S. trade policies, tariffs, and potential restrictions on physician practice ownership models.
Investor Verification Checklist
- OptumRx Replacement: Verify the rate of new customer onboarding and revenue growth in the Pharma segment to confirm if it is successfully offsetting the loss of OptumRx volume.
- Acquisition Integration: Monitor the integration progress and financial contribution of ION and GIA, and the regulatory approval status of the ADSG acquisition.
- Liquidity Management: Assess the impact of the $2.9 billion new debt issuance on future interest expenses and the company's ability to maintain its net leverage ratio covenant (max 3.75-to-1).
- Opioid Settlement Payments: Track actual cash outflows against the $4.9 billion accrued liability to ensure no material deviations in payment schedules.
- GLP-1 Demand: Evaluate the sustainability of sales growth in GLP-1 pharmaceuticals amidst potential supply constraints and reimbursement uncertainties.